AVOS Life Sciences

Table of Contents - Obesity

Disease Etiology 6
Determination of Diagnosis 6
Epidemiology & Patient Population Estimates 7
Theoretical Patient Population 7
Overweight Population 7
Obese Population 7
Addressable Patient Population 9
Treated Patient Population 9
Obesity Patient Population Model 11
Disease & Market Definitions 12
Drug Classes 12
Reduce Energy Intake 12
Nutrient Partitioning/Lipase Inhibitor 12
Increase Energy Expenditure 12
Other 12
Off-Label Use 13
Drugs to Treat Depression 13
Drugs to Treat Seizures 13
Drugs to Treat Diabetes 13
OTC Drugs for Obesity 13
Alli (orlistat) 13
5-HTP/Tryptophan 13
Calcium/Vitamin D 14
Cimetidine 14
Conjugated Linoleic Acid 14
Ephedrine 14
Hoodia 14
Teas 14
Compounds with Questionable Weight-Loss Results 15
Chitosan 15
Chromium 15
Garcinia Cambogia 15
Hypericum 15
Melatonin 15
Leptoprin 16
Bariatric Surgery 16
Restrictive Procedures 16
Malabsorptive Procedures 16
Combination Procedures 17
Forecasting Methodology 17
Market Revenue Forecasts 17
U.S. Obesity Market Model, 2004-2013 19
AVOS Physician Panel Results 21
Physician Treatment Patterns 21
Patient Compliance 23
High Cost 23
Negative Side Effect Profile 23
Behavioral and Lifestyle Changes 23
Physician Product Selection Criteria 24
Cost of Therapy 24
Tolerability 24
Long Term Efficacy 24
Historical Physician Use Patterns 24
Patient Response 25
Availability of Drug Samples 25
Physician Product Ratings & Forecasts of Future Market Trends 25
Market Overview 29
Leading Products 29
Market History 29
Current Market Environment 31
Economic Issues Associated with Obesity 32
Economic Consequences 32
Product Profiles
Xenical 33
U.S. Perspective 33
Worldwide Perspective 34
AVOS Physician Panel Discussions 34
Product History 35
Meridia 36
U.S. Perspective 36
Worldwide Perspective 37
AVOS Physician Panel Discussions 37
Product History 38
Phentermine 39
U.S. Perspective 39
AVOS Physician Panel Discussions 40
Product History 40
Phendimetrazine/Diethylpropion/Benzphetamine 41
U.S. Perspective 41
AVOS Physician Panel Discussions 42
Product History 42
Cetilistat 43
U.S. Perspective 43
Worldwide Perspective 44
AVOS Physician Panel Discussions 44
Rimonabant 45
U.S. Perspective 45
Worldwide Perspective 46
AVOS Physician Panel Discussions 47
Taranabant/CP-945,598/SLV-319 48
U.S. Perspective 49
Product History 50
AVOS Physician Panel Discussions 51
Lorcaserin 52
U.S. Perspective 52
Product History 53
AVOS Physician Panel Discussions 53
Liraglutide 55
U.S. Perspective 55
Product History 56
AVOS Physician Panel Discussions 56
Pramlintide + Leptin 57
U.S. Perspective 57
Worldwide Perspective 58
AVOS Physician Panel Discussions 58
Drugs in Development 59
R&D Overview 59
Cannabinoid-1 Receptor Antagonists 59
Lipase Inhibitors 59
Serotonin Agonists 59
Glucagon-Like Peptide-1 Agonists 59
Amylin Agonist 59
Assessment of R&D Success Rates 60
Products in the Pipeline 61
Phase III (seven agents) 61
Phase II (10 agents) 62
Cover

Production date: December 2007

Order

Print Copy - $5,000

Single Site license PDF - $7,000

Global License PDF - $9,995

Contact Information:

If you wish to see sample pages or to learn more about AVOS Therapeutic Market Reports, contact Mike Goodman
919-475-9695
reports@avoslifesciences.com